Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147145 | 0.90 | FAAH (0.48) | FAAHEPHX2LIPEKMT2AMEN1 | |
| SCHEMBL1147001 | 0.89 | FAAH (0.48) | FAAHEPHX2LIPEL3MBTL1KMT2A | |
| SCHEMBL1147240 | 0.88 | FAAH (0.51) | FAAHEPHX2L3MBTL1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL1147225 | 0.87 | FAAH (0.50) | FAAHEPHX2L3MBTL1KMT2AMEN1 | |
| SCHEMBL15387479 | 0.87 | FAAH (0.46) | FAAHEPHX2LIPEL3MBTL1KMT2A | |
| SCHEMBL1146756 | 0.85 | FAAH (0.63) | FAAHEPHX2KMT2AMEN1MAPT | |
| SCHEMBL1147196 | 0.85 | LIPE (0.52) | FAAHEPHX2LIPE | |
| SCHEMBL1147272 | 0.84 | LIPE (0.58) | FAAHEPHX2LIPETP53MAPT | |
| SCHEMBL1147263 | 0.84 | EPHX2 (0.53) | FAAHEPHX2KMT2AMEN1TP53 | |
| SCHEMBL15387391 | 0.83 | FAAH (0.47) | FAAHEPHX2LIPEL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | claimed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | claimed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | FAAH 2059/4885EPHX2 3415/4885LIPE 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.